Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The E6 proteins of high-risk genital human papillomaviruses (HPV), such as HPV types 16 and 18, possess a conserved C-terminal PDZ-binding motif, which mediates interaction with some cellular PDZ domain proteins. The binding of E6 usually results in their ubiquitin-mediated degradation. The ability of E6 to bind to PDZ domain proteins correlates with the oncogenic potential. Using a yeast two-hybrid system, GST pull-down experiments and coimmunoprecipitations, we identified the protein tyrosine phosphatase H1 (
PTPH1
/PTPN3) as a novel target of the PDZ-binding motif of E6 of HPV16 and 18.
PTPH1
has been suggested to function as
tumour suppressor
protein, since mutational analysis revealed somatic mutations in
PTPH1
in a minor fraction of various human tumours. We show here that HPV16 E6 accelerated the proteasome-mediated degradation of
PTPH1
, which required the binding of E6 to the cellular ubiquitin ligase E6-AP and to
PTPH1
. The endogenous levels of
PTPH1
were particularly low in HPV-positive cervical carcinoma cell lines. The reintroduction of the E2 protein into the HPV16-positive cervical carcinoma cell line SiHa, known to lead to a sharp repression of E6 expression and to induce growth suppression, resulted in an increase of the amount of
PTPH1
. Our data suggest that reducing the level of
PTPH1
may contribute to the oncogenic activity of high-risk genital E6 proteins.
...
PMID:Protein tyrosine phosphatase H1 is a target of the E6 oncoprotein of high-risk genital human papillomaviruses. 1794 17